GeoVax Labs Inc
geovax.comWhat Do They Do?
Develops human vaccines and immunotherapies targeting infectious diseases and solid tumor cancers.
10-K for FY2025, filed Apr 15, 2026GeoVax Labs, Inc. (“GeoVax”, “us”, “we” or the “Company”) is a clinical-stage biotechnology company developing human vaccines and…View ↗
How Do They Make Money?
Government entities pay grants and contracts for vaccine development; GeoVax receives funding as it carries out eligible project work and meets grant conditions. Research partners may also fund preclinical work through collaboration agreements.
10-K for FY2025, filed Apr 15, 2026We have received payments from government entities under non-refundable grants and contracts in support of our vaccine development…View ↗
$2.5M
-
10-K for FY2025, filed Apr 15, 2026
$2.5M ↗
Who Are Their Customers?
Government entities provide grants and contracts for vaccine development, while research partners can fund preclinical work through collaboration agreements.
10-K for FY2025, filed Apr 15, 2026We have received payments from government entities under non-refundable grants and contracts in support of our vaccine development…View ↗
Do Revenues Turn Into Profits?
No. It lost $21.5M in FY2025.
10-K for FY2025, filed Apr 15, 2026
−$21.6MView ↗
10-K for FY2025, filed Apr 15, 2026
−$21.5MView ↗
10-K for FY2025, filed Apr 15, 2026
−$21.5MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 27, 2026
−$4.4MView ↗
- ▼ −18% (Loss)
- vs −$5.4M in Q2 FY2025
-
Aug 28, 2026
Nasdaq determined to delist GeoVax's common stock
GeoVax plans to request a hearing; trading will continue during the appeal process.
Sources
8-K, filed Aug 28, 2026
On August 27, 2026, GeoVax Labs Inc. (the “Company”) received a Staff Determination Letter (the “Letter”) from the Listing Qualifications…View ↗
Growing. Revenue grew 6.5x in 4 years, from $385.5K in FY2021 to $2.5M in FY2025, about 59% a year.
Gedeptin combination treatment
The older report describes GeoVax's gene-directed therapy for advanced head and neck cancers; the latest report also plans to test Gedeptin with an immune checkpoint inhibitor as an initial treatment for eligible patients.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Apr 15, 2026GeoVax Labs, Inc. (“GeoVax” or “the Company”) is a clinical-stage biotechnology company developing human vaccines and immunotherapies…View ↗
The Company’s lead clinical program in oncology is Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which recently completed…View ↗
Who Do They Compete With?
Competes with Sanofi, GSK, Merck, Mitsubishi Tanabe, Takeda, Pfizer, Dynavax, Novavax, Moderna, BioNTech, Bavarian Nordic, Advaxis, Immune Design, Oncothyreon, Roche Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, NewLink Genetics, Johnson & Johnson, and Inovio
10-K for FY2025, filed Apr 15, 2026We face general market competition from several subsectors of the vaccine development field, including large, multinational pharmaceutical…View ↗
Loading...
